Tenaya Therapeutics, Inc. Operating Expenses
Tenaya Therapeutics, Inc. (TNYA) reported Operating Expenses of $45.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- Tenaya Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $45.20M, a 87.68% increase year-over-year.
- Tenaya Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $20.29M, a 26.32% decline year-over-year.
- Tenaya Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $20.77M, a 15.73% decline year-over-year.
- Tenaya Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $20.94M, a 21.62% decline year-over-year.
- Tenaya Therapeutics, Inc. operating expenses for fiscal 2025 was $93.33M, a 19.51% decline from fiscal 2024.
- Tenaya Therapeutics, Inc. operating expenses for fiscal 2024 was $115.95M, a 11.62% decline from fiscal 2023.
- Tenaya Therapeutics, Inc. operating expenses for fiscal 2023 was $131.19M, a 4.44% increase from fiscal 2022.
- Tenaya Therapeutics, Inc. operating expenses for fiscal 2022 was $125.62M, a 72.54% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.20M 10-Q · filed 2026-08-05 | $65.49M 10-Q · filed 2026-08-05 | $86.26M derived: sum of 3 quarters · filed 2026-08-05 | $107.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $20.29M 10-Q · filed 2026-05-06 | $41.06M derived: sum of 2 quarters · filed 2026-05-06 | $62.00M derived: sum of 3 quarters · filed 2026-05-06 | $86.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $20.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $41.71M derived: sum of 2 quarters · filed 2026-03-11 | $65.79M derived: sum of 3 quarters · filed 2026-08-05 | $93.33M 10-K · filed 2026-03-11 |
| 2025-09-30 | $20.94M 10-Q · filed 2025-11-10 | $45.02M derived: sum of 2 quarters · filed 2026-08-05 | $72.56M 10-Q · filed 2025-11-10 | $97.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $24.08M 10-Q · filed 2026-08-05 | $51.62M 10-Q · filed 2026-08-05 | $76.27M derived: sum of 3 quarters · filed 2026-08-05 | $102.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $27.54M 10-Q · filed 2026-05-06 | $52.19M derived: sum of 2 quarters · filed 2026-05-06 | $78.90M derived: sum of 3 quarters · filed 2026-05-06 | $109.72M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $24.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $51.36M derived: sum of 2 quarters · filed 2026-03-11 | $82.19M derived: sum of 3 quarters · filed 2026-03-11 | $115.95M 10-K · filed 2026-03-11 |
| 2024-09-30 | $26.71M 10-Q · filed 2025-11-10 | $57.53M derived: sum of 2 quarters · filed 2025-11-10 | $91.30M 10-Q · filed 2025-11-10 | $122.74M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $30.82M 10-Q · filed 2025-08-06 | $64.58M 10-Q · filed 2025-08-06 | $96.03M derived: sum of 3 quarters · filed 2025-08-06 | $126.95M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $33.76M 10-Q · filed 2025-05-07 | $65.21M derived: sum of 2 quarters · filed 2025-05-07 | $96.13M derived: sum of 3 quarters · filed 2025-05-07 | $131.23M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $31.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $62.37M derived: sum of 2 quarters · filed 2025-03-10 | $97.47M derived: sum of 3 quarters · filed 2025-03-10 | $131.19M 10-K · filed 2025-03-10 |
| 2023-09-30 | $30.92M 10-Q · filed 2024-11-06 | $66.02M derived: sum of 2 quarters · filed 2024-11-06 | $99.75M 10-Q · filed 2024-11-06 | $134.30M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $35.10M 10-Q · filed 2024-08-08 | $68.83M 10-Q · filed 2024-08-08 | $103.38M derived: sum of 3 quarters · filed 2024-08-08 | $134.68M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $33.72M 10-Q · filed 2024-05-14 | $68.27M derived: sum of 2 quarters · filed 2024-05-14 | $99.57M derived: sum of 3 quarters · filed 2024-05-14 | $128.19M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $34.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $65.85M derived: sum of 2 quarters · filed 2024-03-18 | $94.47M derived: sum of 3 quarters · filed 2024-03-18 | $125.62M 10-K · filed 2024-03-18 |
| 2022-09-30 | $31.30M 10-Q · filed 2023-11-08 | $59.92M derived: sum of 2 quarters · filed 2023-11-08 | $91.07M 10-Q · filed 2023-11-08 | $117.23M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $28.62M 10-Q · filed 2023-08-09 | $59.77M 10-Q · filed 2023-08-09 | $85.94M derived: sum of 3 quarters · filed 2023-08-09 | $104.24M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $31.15M 10-Q · filed 2023-05-10 | $57.32M derived: sum of 2 quarters · filed 2023-05-10 | $75.62M derived: sum of 3 quarters · filed 2023-05-10 | $90.86M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $26.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $44.46M derived: sum of 2 quarters · filed 2023-03-08 | $59.70M derived: sum of 3 quarters · filed 2023-03-08 | $72.81M 10-K · filed 2023-03-08 |
| 2021-09-30 | $18.30M 10-Q · filed 2022-11-10 | $33.54M derived: sum of 2 quarters · filed 2022-11-10 | $46.64M 10-Q · filed 2022-11-10 | $56.96M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $15.24M 10-Q · filed 2022-08-10 | $28.34M 10-Q · filed 2022-08-10 | $38.66M derived: sum of 3 quarters · filed 2022-08-10 | $49.12M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $13.11M 10-Q · filed 2022-05-11 | $23.43M derived: sum of 2 quarters · filed 2022-05-11 | $33.88M derived: sum of 3 quarters · filed 2022-05-11 | $42.75M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $10.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $20.77M derived: sum of 2 quarters · filed 2022-03-23 | $29.65M derived: sum of 3 quarters · filed 2022-03-23 | $38.91M 10-K · filed 2022-03-23 |
| 2020-09-30 | $10.45M 10-Q · filed 2021-11-10 | $19.32M derived: sum of 2 quarters · filed 2021-11-10 | $28.59M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $8.87M 10-Q · filed 2021-09-08 | $18.14M 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |